De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: Molecular mechanisms and correlation with rituximab sensitivity

De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: Molecular mechanisms and correlation with rituximab sensitivity

CD20 is expressed in most B-cell lymphomas and is a critical molecular target of rituximab. Some B-cell lymphomas show aberrant CD20 expression, and rituximab use in these patients is controversial. Here we show both the molecular mechanisms and the clinical significance of de novo diffuse large B-c...

Full description

Bibliographic Details
Main Authors: Tokunaga, Takashi, Tomita, Akihiro, Sugimoto, Keiki, Shimada, Kazuyuki, Iriyama, Chisako, Hirose, Tatsuya, Shirahata-Adachi, Mizuho, Suzuki, Yasuhiro, Mizuno, Hiroki, Kiyoi, Hitoshi, Asano, Naoko, Nakamura, Shigeo, Kinoshita, Tomohiro, Naoe, Tomoki
Format: Online
Language:English
Published: BlackWell Publishing Ltd 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317883/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317883/

Similar Items